M&A With Big Pharma: Due Diligence Issues That Can Affect a Deal

The success of life sciences companies will depend on products and services not yet found in a companies offerings in the next decade. Much of those products will be brought to companies through the merger and acquisitions of small to mid-sized companies. This panel discussed:

• When is the right time to get acquired?
• What is the survival rate of c-suite after an acquisition?
• Why is an acquisition better than a collaboration?
• What are the key issues in the due diligence process that can hurt the value of the deal?
• How does big pharma prepare for pricing negotiations and how can a smaller seller be prepared
• What types of steps can be taken to prepare a forecast that drives value negotiations
• How can this analysis be leverage in negotiating a collaborative or co-partner agreement

Presenters included:

• Todd Boudreau, Senior Counsel, Private Equity & Venture Capital Practice,  Foley
• Dr. Ton Bunt, Senior Advisor, JSB Partners LP
• Sven Riethmueller, Of Counsel, Private Equity & Venture Capital, Foley
• David Schechner, Managing Director, Canaccord Adams
• Shane Senior, Managing Director, Crosstree Capital Partners Inc.